Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. The present study investigated and compared the effects of THC-dominant and THCCBD equivalent cannabis on simulated driving and cognitive performance. In a randomized, double-blind, within-subjects crossover design, healthy volunteers (n 14) with a history of light cannabis use attended three outpatient experimental test sessions in which simulated driving and cognitive performance were assessed at two timepoints (20-60 min and 200-240 min) following vaporization of 125 mg THC-dominant (11% THC < 1% CBD), THCCBD equivalent (11% THC, 11% CBD), or placebo (< 1% THCCBD) cannabis. Both active cannabis types increased lane weaving during a car-following task but had little effect on other driving performance measures. Active cannabis types impaired performance on the Digit Symbol Substitution Task (DSST), Divided Attention Task (DAT) and Paced Auditory Serial Addition Task (PASAT) with impairment on the latter two tasks worse with THCCBD equivalent cannabis. Subjective drug effects (e.g., stoned) and confidence in driving ability did not vary with CBD content. Peak plasma THC concentrations were higher following THCCBD equivalent cannabis relative to THC-dominant cannabis, suggesting a possible pharmacokinetic interaction. Cannabis containing equivalent concentrations of CBD and THC appears no less impairing than THC-dominant cannabis, and in some circumstances, CBD may actually exacerbate THC-induced impairment.